215 related articles for article (PubMed ID: 36150518)
1. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France.
Nguyen NN; Houhamdi L; Delorme L; Colson P; Gautret P
Emerg Infect Dis; 2022 Nov; 28(11):2341-2343. PubMed ID: 36150518
[TBL] [Abstract][Full Text] [Related]
2. Early SARS-CoV-2 Reinfections within 60 Days and Implications for Retesting Policies.
Nevejan L; Cuypers L; Laenen L; Van Loo L; Vermeulen F; Wollants E; Van Hecke I; Desmet S; Lagrou K; Maes P; André E
Emerg Infect Dis; 2022 Aug; 28(8):1729-1731. PubMed ID: 35738346
[TBL] [Abstract][Full Text] [Related]
3. Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain.
Rodríguez-Grande C; Estévez A; Palomino-Cabrera R; Molero-Salinas A; Peñas-Utrilla D; Herranz M; Sanz-Pérez A; Alcalá L; Veintimilla C; Catalán P; Martínez-Laperche C; Alonso R; Muñoz P; Pérez-Lago L; de Viedma DG;
Emerg Infect Dis; 2023 Jun; 29(6):1154-1161. PubMed ID: 37130503
[TBL] [Abstract][Full Text] [Related]
4. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 reinfections in the pediatric cohort-a single-center experience.
Arslan A; Sahbudak Bal Z; Erci E; Yıldırım Arslan S; Bilen NM; Avcu G; Çiçek C; Ozkinay F; Kurugol Z
J Trop Pediatr; 2023 Dec; 70(1):. PubMed ID: 38150674
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
[TBL] [Abstract][Full Text] [Related]
7. Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-September 2022.
Foulkes S; Monk EJM; Sparkes D; Hettiarachchi N; Milligan ID; Munro K; Taylor-Kerr A; Platt N; Howells A; Kyaw JYA; Adaji E; Gallagher E; Khawam J; Wellington E; Price L; Crossman D; Norman C; de Lacy E; Cromey L; Corrigan D; Lackenby A; Barbero P; Elegunde B; Zambon M; Chand MA; Brown CS; Islam J; Atti A; Hopkins S; Hall VJ; Cole MJ;
Emerg Infect Dis; 2023 Jan; 29(1):184-188. PubMed ID: 36454718
[TBL] [Abstract][Full Text] [Related]
8. Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022.
Sofonea MT; Roquebert B; Foulongne V; Morquin D; Verdurme L; Trombert-Paolantoni S; Roussel M; Bonetti JC; Zerah J; Haim-Boukobza S; Alizon S
Emerg Infect Dis; 2022 Jul; 28(7):1355-1365. PubMed ID: 35642476
[TBL] [Abstract][Full Text] [Related]
9. [Prediction of protection probability against Omicron BA.1, BA.4 and BA.5 variants in symptomatic infections with prototype strain based on neutralization antibody levels].
Lu WY; Chen XH; Zheng N; Yu HJ
Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1429-1434. PubMed ID: 37150697
[No Abstract] [Full Text] [Related]
10. Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021.
Ruff J; Zhang Y; Kappel M; Rathi S; Watkins K; Zhang L; Lockett C
Emerg Infect Dis; 2022 Oct; 28(10):1977-1981. PubMed ID: 35969420
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019.
Awasthi M; Golding H; Khurana S
Clin Infect Dis; 2023 Feb; 76(3):e503-e506. PubMed ID: 35925647
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022.
Bastard J; Taisne B; Figoni J; Mailles A; Durand J; Fayad M; Josset L; Maisa A; van der Werf S; Parent du Châtelet I; Bernard-Stoecklin S
Euro Surveill; 2022 Mar; 27(13):. PubMed ID: 35362406
[TBL] [Abstract][Full Text] [Related]
13. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
Morris CP; Eldesouki RE; Sachithanandham J; Fall A; Norton JM; Abdullah O; Gallagher N; Li M; Pekosz A; Klein EY; Mostafa HH
Clin Infect Dis; 2023 Apr; 76(7):1276-1284. PubMed ID: 36366857
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province.
Wang Y; Liang J; Yang H; Zhu L; Hu J; Xiao L; Huang Y; Dong Y; Wu C; Zhang J; Zhou X
Front Public Health; 2023; 11():1256768. PubMed ID: 37780420
[TBL] [Abstract][Full Text] [Related]
15. History of primary-series and booster vaccination and protection against Omicron reinfection.
Chemaitelly H; Ayoub HH; Tang P; Coyle PV; Yassine HM; Al Thani AA; Al-Khatib HA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
Sci Adv; 2023 Oct; 9(40):eadh0761. PubMed ID: 37792951
[TBL] [Abstract][Full Text] [Related]
16. Serial Intervals and Incubation Periods of SARS-CoV-2 Omicron and Delta Variants, Singapore.
Zeng K; Santhya S; Soong A; Malhotra N; Pushparajah D; Thoon KC; Yeo B; Ho ZJM; Cheng MCI
Emerg Infect Dis; 2023 Apr; 29(4):814-817. PubMed ID: 36878009
[TBL] [Abstract][Full Text] [Related]
17. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
[TBL] [Abstract][Full Text] [Related]
18. "Rapid reinfections with different or same Omicron SARS-CoV-2 sub-variants".
Vera-Lise I; Dominik E; Elisabeth R; Kerstin H; Raffael F; Angelika X; Tibor A; Jusztina B; Ursula K; Jochen H; David K; John-Hendrik J
J Infect; 2022 Oct; 85(4):e96-e98. PubMed ID: 35810939
[No Abstract] [Full Text] [Related]
19. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years - 18 U.S. Jurisdictions, September 2021-December 2022.
Ma KC; Dorabawila V; León TM; Henry H; Johnson AG; Rosenberg E; Mansfield JA; Midgley CM; Plumb ID; Aiken J; Khanani QA; Auche S; Bayoumi NS; Bennett SA; Bernu C; Chang C; Como-Sabetti KJ; Cueto K; Cunningham S; Eddy M; Falender RA; Fleischauer A; Frank DM; Harrington P; Hoskins M; Howsare A; Ingaiza LM; Islam AS; Jensen SA; Jones JM; Kambach G; Kanishka F; Levin Y; Masarik JF; Meyer SD; Milroy L; Morris KJ; Olmstead J; Olsen NS; Omoike E; Patel K; Pettinger A; Pike MA; Reed IG; Slocum E; Sutton M; Tilakaratne BP; Vest H; Vostok J; Wang JS; Watson-Lewis L; Wienkes HN; Hagen MB; Silk BJ; Scobie HM
MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(25):683-689. PubMed ID: 37347715
[TBL] [Abstract][Full Text] [Related]
20. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
Yu W; Guo Y; Hu T; Liu Y; Fan Q; Guo L; Zheng B; Kong Y; Zhu H; Yu J; Chen S; Zhang Y; Wang J; Li F; Yang F; Wang Y; Zhu Y; Huang Y; Shen Z; Ruan Y; Mao R; Zhang J
J Med Virol; 2023 Aug; 95(8):e28997. PubMed ID: 37537950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
